What happens when you take orforglipron with st. john's wort?
Orforglipron (Foundayo) is a once-daily GLP-1 receptor agonist tablet approved to help adults with obesity, or overweight with a weight-related condition, lose weight and keep it off, together with diet and exercise. St. John's wort (Hypericum perforatum) is an herbal product sold for low mood. The herb speeds up the enzyme that breaks down orforglipron, so less of the medicine may stay in the body.
- Orforglipron is cleared by CYP3A4. The Foundayo label says it is metabolized primarily by the liver enzyme CYP3A4.
- St. John's wort induces CYP3A4. The FDA lists it as a strong CYP3A inducer: over days of use, the body makes more of the enzyme.
- Orforglipron levels fall. With carbamazepine, another strong inducer, orforglipron exposure dropped by 82%.
- The medicine may work less well. The label says lower exposure may reduce the effectiveness of Foundayo.
Why is this important?
The Foundayo label tells prescribers to avoid strong CYP3A4 inducers with Foundayo. It does not name St. John's wort, but the FDA places the herb in that same strong-inducer group. People may not think of an herbal product as a medicine and may not mention it, so the prescriber may not know.
The concern is mainly loss of effect: less weight loss for the same dose. There is a second, quieter issue. Induction fades over about a week after the herb is stopped, so orforglipron levels would climb back up, which could bring more of its usual side effects such as nausea, vomiting and diarrhea. That is why a change in either one is best planned with your prescriber.
What should you do?
Before starting orforglipron: Tell your prescriber about every herbal product you take, including St. John's wort in teas or blends.
While taking orforglipron: Avoid St. John's wort unless your prescriber agrees. Check the labels of mood, sleep, stress and menopause blends, where the herb is often included.
If you already take both: Do not stop or change orforglipron on your own. Talk to your prescriber or pharmacist before stopping the herb too, especially if you use it for low mood, so your mood and your orforglipron dose can be looked after together.
Which specific products are affected?
On the medication side, this applies to Foundayo (orforglipron) tablets.
On the herb side, it applies to any Hypericum perforatum product: capsules, tablets, tinctures, teas, and multi-herb blends for mood, sleep, stress or menopause. Products with more hyperforin, a constituent of the herb, induce the enzyme more; low-hyperforin products induce it less, but none has been tested with orforglipron.
The science behind it
The Foundayo prescribing information (DailyMed, sections 2.2, 7.1 and 12.3) says to avoid concomitant use with strong CYP3A4 inducers because induction decreases Foundayo exposure, "which may reduce the effectiveness of FOUNDAYO." In its drug interaction table, carbamazepine (a strong inducer) lowered orforglipron AUC by 82% and peak level by 55%; a computer model predicted a 61% drop with efavirenz (a moderate inducer). With moderate inducers, the label says to monitor effectiveness. Orforglipron has an elimination half-life of about 29 to 49 hours.
The FDA table of drugs that interact with CYP enzymes (fda.gov) lists St. John's wort as a strong CYP3A inducer, with a footnote that its effect varies widely and is preparation dependent.
Human studies show how strong the herb's effect can be. Dresser GK, et al. (Clin Pharmacol Ther. 2003; PMID 12545142) gave 21 healthy young adults St. John's wort for 12 days; the oral clearance of midazolam, a CYP3A test drug, rose about 2.7-fold. Mueller SC, et al. (Eur J Clin Pharmacol. 2006; PMID 16341856) tested six St. John's wort products in 42 healthy men for 14 days: a high-hyperforin extract cut midazolam exposure by 79.4%, and a product almost free of hyperforin cut it by 21.1%. Imai H, et al. (Br J Clin Pharmacol. 2008; PMID 18294328) found that in 12 healthy men, CYP3A activity returned to baseline about 7 days after stopping the herb.
What was not shown: no study has given St. John's wort with orforglipron, and no study has measured weight loss in people taking both. The warning is based on the label rule for strong inducers and the FDA's classification of the herb.
Frequently Asked Questions
Can I take St. John's wort with Foundayo?
It is best avoided unless your prescriber agrees. The Foundayo label says to avoid strong CYP3A4 inducers, and the FDA classes St. John's wort as one.
Will St. John's wort stop Foundayo from working?
It may make it work less well. A strong inducer cut orforglipron exposure by 82% in a study; the effect of St. John's wort itself has not been measured and depends on the product.
Is St. John's wort tea a problem too?
It can be. Teas, tinctures and blends contain the same herb, though the amount of hyperforin varies. Check labels and ask your pharmacist.
What if I stop St. John's wort?
The enzyme effect fades over about a week, so orforglipron levels would rise back toward normal, which could bring more nausea or other side effects. Plan the change with your prescriber or pharmacist.
Does this apply to other weight-loss medicines?
This page is about orforglipron, whose label sets the rule on strong CYP3A4 inducers. Other medicines have their own labels, so ask your pharmacist about St. John's wort with any of them.
Key takeaways
- Orforglipron is cleared mainly by CYP3A4, and its label says to avoid strong CYP3A4 inducers.
- The FDA classes St. John's wort as a strong CYP3A inducer, with effects that vary by product.
- A strong inducer cut orforglipron exposure by 82%; the herb itself has not been tested with it.
- The main risk is that orforglipron works less well.
- Tell your prescriber about St. John's wort, and plan any change to either one with your prescriber or pharmacist.
